Header cover image

Chinese (SSE) Biotech Industry Analysis

UpdatedMar 24, 2025
DataAggregated Company Financials
Companies72
  • 7D-1.9%
  • 3M-0.2%
  • 1Y-12.1%
  • YTD6.0%

Over the last 7 days, the Biotech industry has dropped 1.9%, driven by Imeik Technology DevelopmentLtd declining 8.0%. The industry has fallen 12% in the last year. Earnings are forecast to grow by 42% annually.

Industry Valuation and Performance

Has the Chinese Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 25 Mar 2025CN¥850.7bCN¥136.2bCN¥11.7b32.1x72.5x6.2x
Thu, 20 Feb 2025CN¥836.3bCN¥136.0bCN¥10.8b34.3x77.7x6.1x
Sat, 18 Jan 2025CN¥800.1bCN¥136.0bCN¥10.8b32.7x74.4x5.9x
Mon, 16 Dec 2024CN¥888.3bCN¥136.0bCN¥10.8b33.9x82.6x6.5x
Wed, 13 Nov 2024CN¥980.2bCN¥141.7bCN¥11.2b39x87.5x6.9x
Fri, 11 Oct 2024CN¥947.5bCN¥154.1bCN¥14.5b37.6x65.6x6.1x
Sun, 08 Sep 2024CN¥758.2bCN¥154.2bCN¥14.5b30.5x52.2x4.9x
Tue, 06 Aug 2024CN¥819.4bCN¥161.2bCN¥17.3b31.2x47.3x5.1x
Thu, 04 Jul 2024CN¥816.5bCN¥161.1bCN¥17.3b30.1x47.2x5.1x
Sat, 01 Jun 2024CN¥906.1bCN¥161.1bCN¥17.3b35.3x52.4x5.6x
Mon, 29 Apr 2024CN¥927.1bCN¥161.8bCN¥18.3b35x50.8x5.7x
Wed, 27 Mar 2024CN¥980.5bCN¥164.4bCN¥21.9b36.7x44.9x6x
Fri, 23 Feb 2024CN¥979.8bCN¥167.9bCN¥21.4b33.8x45.7x5.8x
Sun, 21 Jan 2024CN¥1.0tCN¥167.9bCN¥21.4b35.7x46.9x6x
Tue, 19 Dec 2023CN¥1.1tCN¥168.1bCN¥21.5b39.7x50.9x6.5x
Thu, 16 Nov 2023CN¥1.1tCN¥168.1bCN¥21.5b41.4x51.7x6.6x
Sat, 14 Oct 2023CN¥1.1tCN¥170.9bCN¥25.2b44.3x43.1x6.4x
Mon, 11 Sep 2023CN¥998.8bCN¥170.7bCN¥25.3b37.5x39.4x5.8x
Wed, 09 Aug 2023CN¥1.1tCN¥174.4bCN¥28.4b38.7x37x6x
Fri, 07 Jul 2023CN¥1.1tCN¥177.4bCN¥29.3b38.7x36.2x6x
Sun, 04 Jun 2023CN¥1.1tCN¥177.4bCN¥29.3b42x38.3x6.3x
Tue, 02 May 2023CN¥1.2tCN¥180.7bCN¥31.8b43.4x38.6x6.8x
Thu, 30 Mar 2023CN¥1.2tCN¥186.5bCN¥37.1b39.4x33.1x6.6x
Sat, 25 Feb 2023CN¥1.3tCN¥179.4bCN¥37.9b44.2x33.9x7.2x
Mon, 23 Jan 2023CN¥1.3tCN¥179.6bCN¥38.2b42.6x34.9x7.4x
Wed, 21 Dec 2022CN¥1.2tCN¥175.6bCN¥37.9b37.5x31.5x6.8x
Fri, 18 Nov 2022CN¥1.3tCN¥175.5bCN¥37.9b41.5x33.9x7.3x
Sun, 16 Oct 2022CN¥1.2tCN¥174.5bCN¥40.3b33.7x29.8x6.9x
Tue, 13 Sep 2022CN¥1.2tCN¥174.0bCN¥40.1b34x30.6x7.1x
Thu, 11 Aug 2022CN¥1.2tCN¥171.2bCN¥43.3b35.4x28.9x7.3x
Sat, 09 Jul 2022CN¥1.3tCN¥168.1bCN¥42.4b38.7x31.7x8x
Mon, 06 Jun 2022CN¥1.2tCN¥168.1bCN¥42.4b36.9x28x7.1x
Wed, 04 May 2022CN¥1.2tCN¥163.1bCN¥35.9b36.8x33.5x7.4x
Fri, 01 Apr 2022CN¥1.5tCN¥155.0bCN¥41.5b44.4x35.3x9.4x
Price to Earnings Ratio

35.3x


Total Market Cap: CN¥1.5tTotal Earnings: CN¥41.5bTotal Revenue: CN¥155.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Biotech Industry Price to Earnings3Y Average 45.3x202320242025
Current Industry PE
  • Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 72.5x which is higher than its 3-year average PE of 45.3x.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have declined 34% per year over the last three years,
  • Revenues have also declined 4.2% per year.
  • This means overall sales from these companies are declining and profits are subsequently falling as well.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare industry?

CN Market-2.08%
Healthcare-1.71%
Biotech-1.94%
Biotech-1.94%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
688192 Dizal (Jiangsu) PharmaceuticalCN¥46.693.0%
+CN¥559.6m
9.7%PS54.1x
688278 Xiamen Amoytop BiotechCN¥80.331.7%
+CN¥553.2m
20.7%PE39.5x
600645 Vcanbio Cell & Gene EngineeringCN¥23.195.5%
+CN¥551.6m
40.5%PE98.4x
688336 Sunshine Guojian Pharmaceutical (Shanghai)CN¥27.912.4%
+CN¥400.9m
17.7%PE23.5x
688136 Kexing BiopharmCN¥22.778.6%
+CN¥357.9m
38.6%PE142.8x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

688136

CN¥22.77

Kexing Biopharm

7D

8.6%

1Y

38.6%

300896

CN¥187.61

Imeik Technology DevelopmentLtd

7D

-8.0%

1Y

-21.3%

688192

CN¥46.69

Dizal (Jiangsu) Pharmaceutical

7D

3.0%

1Y

9.7%

688687

CN¥24.30

Beijing Kawin Technology Share-Holding

7D

4.5%

1Y

-19.8%

300676

CN¥54.73

BGI Genomics

7D

-9.9%

1Y

29.7%

300122

CN¥24.72

Chongqing Zhifei Biological Products

7D

-3.2%

1Y

-46.9%

002252

CN¥6.82

Shanghai RAAS Blood Products

7D

-3.5%

1Y

-3.3%

688298

CN¥31.90

Zhejiang Orient Gene Biotech

7D

4.0%

1Y

4.1%